Welcome to our dedicated page for Mountain Crest news (Ticker: MCAGR), a resource for investors and traders seeking the latest updates and insights on Mountain Crest stock.
Mountain Crest Acquisition Corp. V (MCAGR) provides investors with a centralized hub for tracking this Special Purpose Acquisition Company's strategic developments. This page aggregates official press releases, regulatory filings, and merger-related updates essential for understanding the company's progress in identifying business combinations.
Access real-time announcements regarding potential acquisitions, SEC compliance status changes, and corporate governance updates. The curated collection serves analysts and investors with timely insights into MCAGR's operational milestones while maintaining strict adherence to factual reporting standards.
Key focus areas include merger negotiations, Nasdaq listing compliance, capital deployment strategies, and shareholder communications. All content is vetted for relevance to the company's core mission as a blank check entity seeking to create value through disciplined target identification.
Bookmark this page for streamlined access to primary source documents and official statements. Regularly updated content ensures stakeholders remain informed about MCAGR's position within the evolving SPAC marketplace.
Mountain Crest Acquisition Corp. V (NASDAQ: MCAG) received a deficiency notification from Nasdaq on September 13, 2024, due to delayed filing of its Q1 and Q2 2024 10-Q reports. The company has until September 16, 2024, to submit a compliance plan and may receive a maximum 180-day extension until October 14, 2024. MCAG has made progress by filing its Q1 10-Q on September 13 and submitting a compliance plan on September 16. The company also filed its previously delayed 2023 10-K on August 26, 2024. MCAG is a blank check company formed to effect a business combination with other businesses.
CUBEBIO, a Korean company with innovative early-stage cancer diagnosis technology using urine, has entered into a business combination agreement with Mountain Crest Acquisition Corp. V (MCAG). The deal aims to make CUBEBIO a publicly listed company on Nasdaq. Key details include:
1. Pre-transaction equity value for CUBEBIO: $375 million
2. Potential earn-out payment: $245 million if 2026 revenue reaches $42.7 million
3. Expected closing: First quarter of 2025
The transaction involves a merger and share swap, with CUBEBIO shareholders receiving PubCo Ordinary Shares. This marks Mountain Crest's fifth SPAC business combination, highlighting their experience in such deals.
Mountain Crest Acquisition Corp. V (NASDAQ: MCAG) has received a deficiency notification from Nasdaq due to delayed filing of its Annual Report (Form 10-K) for 2023 and Quarterly Report (Form 10-Q) for Q1 2024. This non-compliance with Nasdaq Listing Rule 5250(c)(1) requires the company to submit a compliance plan by September 2, 2024. Nasdaq may grant an extension until October 14, 2024 for the company to regain compliance. MCAG intends to file the required reports or submit a compliance plan before the deadline. The company is working to complete and file the Form 10-K and Form 10-Q as soon as possible, though no specific timing assurances were provided.
Mountain Crest Acquisition Corp. V and CUBEBIO Co., have entered a non-binding term sheet for a potential business combination. CUBEBIO, a Korea-based company, with innovative cancer diagnosis technology using urine, aims to become a public company listed on The Nasdaq Stock Market. The pre-transaction equity value is $620 million, subject to adjustments. Global Fund is advising CUBEBIO. Mountain Crest V's management expresses excitement about the growth potential from CUBEBIO's technology.
FAQ
What is the current stock price of Mountain Crest (MCAGR)?
